Eisenmenger syndrome represents the advanced and irreversible stage of certain congenital heart diseases characterized by a prolonged presence of a left-to-right shunt, either uncorrected or uncorrectable, which over time leads to the development of severe pulmonary hypertension and subsequent reversal of the flow (right-to-left shunt), resulting in chronic central cyanosis and multiorgan damage. This syndrome is one of the most feared and complex complications of untreated congenital heart diseases and today serves as a paradigmatic pathophysiological model of transition from a "benign" cardiac condition to a severe pulmonary and systemic vascular disease. The syndrome was first described by Victor Eisenmenger in 1897.
The etiology of Eisenmenger syndrome is strictly related to congenital cardiac malformations causing a non-restrictive left-to-right shunt.
The main congenital heart diseases responsible, if not treated early, include:
The presence of any of these defects, if not diagnosed and corrected within the first years of life, results in a persistent volume and pressure overload on the pulmonary circulation, which is the triggering factor for the development of the syndrome.
Risk factors facilitating progression to Eisenmenger include lack of early correction of the congenital defect, presence of a large and non-restrictive defect, genetic predisposition to abnormal vascular response (including polymorphisms or mutations in genes such as BMPR2, NOTCH1, ENG), complex genetic syndromes (e.g., trisomy 21), absence of specialized follow-up, unfavorable socioeconomic conditions, and infections or events exacerbating pulmonary endothelial damage.
The pathogenesis of Eisenmenger syndrome is based on progressive pulmonary vascular impairment induced by a non-restrictive left-to-right shunt.
In the early stages of life, the congenital defect causes a chronic increase in flow and pressure in the pulmonary circulation. This hemodynamic overload imposes mechanical stress on the pulmonary arterial walls, causing endothelial injury and activating a cascade of cellular and molecular responses involving inflammation, release of vasoconstrictive mediators, smooth muscle cell proliferation, and extracellular matrix remodeling.
Over time, the pulmonary vascular tissue undergoes progressive structural remodeling, well described by the Heath-Edwards histopathological classification, which distinguishes several evolutionary stages of vascular damage:
As these processes progress, the pulmonary vascular resistance rises until it exceeds systemic resistance: at this point, the pressure gradient reverses and venous blood from the right circulation is diverted into the systemic arterial circulation through the cardiac defect. This is the critical moment marking the transition to true Eisenmenger syndrome, characterized by the establishment of a right-to-left shunt, systemic hypoxemia, and chronic central cyanosis.
From a pathophysiological perspective, Eisenmenger syndrome causes profound disturbance of hemodynamic balance and a cascade of systemic effects related to chronic hypoxemia and irreversible pulmonary hypertension.
The systemic pathophysiology of the syndrome revolves around three fundamental mechanisms:
These mechanisms progressively intertwine, impairing perfusion and function of various organs, particularly the brain, kidneys, liver, and bone marrow, contributing to clinical deterioration and poor prognosis.
The shunt reversal causes a mixture of venous blood into the arterial circulation, with persistent reduction of systemic saturation and consequent central cyanosis. This hypoxic state stimulates erythropoiesis (polycythemia), increasing blood viscosity and predisposing to thrombotic events and microcirculatory dysfunction.
The right ventricle, chronically overloaded by work against the high pulmonary vascular resistance, undergoes remodeling, hypertrophy, and eventually systolic and diastolic dysfunction. Its reduced adaptive capacity leads to signs and symptoms of right heart failure, including systemic congestion and decreased cardiac output.
Systemically, chronic tissue hypoperfusion and cyanosis cause multiple secondary complications: renal alterations with proteinuria and progressive glomerular dysfunction, coagulation disturbances with bleeding and thrombotic tendencies, hepatic congestion with impaired liver function and, in advanced cases, congestive hepatopathy, increased risk of ischemic or hemorrhagic stroke (including paradoxical embolism), and growth and developmental delays in pediatric patients.
Additionally, neurohormonal adaptations and persistent peripheral vasodilation worsen hypoxia and contribute to hemodynamic instability. This complex pathophysiological picture explains the high morbidity and mortality of Eisenmenger syndrome, whose management demands a multidisciplinary approach and vigilant monitoring of systemic complications.
The clinical presentation of Eisenmenger syndrome reflects the complex interplay between advanced pulmonary hypertension, chronic hypoxemia, and multiorgan compensatory adaptations. The clinical picture is highly variable, in terms of both age at onset and progression speed, and is strongly influenced by the type and size of the underlying cardiac defect as well as the individual pulmonary vascular response.
In the early stages, patients may be asymptomatic or present mild symptoms such as reduced exercise tolerance, tachypnea, or easy fatigability during physical activity, often attributed to common pediatric conditions. Progressive pulmonary vascular damage and increasing resistance lead over time to more specific and severe symptoms.
The cardinal clinical sign is persistent central cyanosis, caused by the admixture of deoxygenated blood into the systemic circulation through the right-to-left shunt. Cyanosis is evident at the lips, oral mucosa, nail beds, and in advanced stages also affects the skin and deeper tissues. Chronic hypoxia stimulates secondary erythropoiesis, resulting in polycythemia, which may cause headache, dizziness, visual disturbances, pruritus, and increased thrombotic risk.
Dyspnea is one of the most common and progressively limiting symptoms. It initially occurs on exertion but may develop at rest with disease progression. Exercise intolerance is often accompanied by chronic fatigue, generalized weakness, and poor growth and development in pediatric patients.
Palpitations and syncope are also frequent, reflecting atrial or ventricular arrhythmias secondary to hypertrophy and myocardial fibrosis, as well as cerebral hypoxia. In some cases, syncope can be triggered by minimal effort, Valsalva maneuvers, or rapid nonsustained arrhythmias.
With disease progression, polycythemia may become severe, increasing blood viscosity and predisposing to both venous and arterial thromboembolic events. Bleeding manifestations such as epistaxis, gingival bleeding, and hemoptysis are common and aggravated by platelet dysfunction and coagulation abnormalities induced by chronic hypoxia and blood stasis.
Another characteristic finding is digital clubbing (hippocratic fingers), the "watch-glass" deformity of distal phalanges, resulting from chronic hypoxemia and periungual soft tissue hyperplasia.
On physical examination, besides cyanosis and clubbing, signs of right ventricular hypertrophy and failure may be present: jugular venous distension, hepatomegaly, peripheral edema, ascites, and, in advanced cases, systemic congestion. Cardiac auscultation may reveal accentuated pulmonary second sound, systolic or diastolic murmurs variable depending on the original defect and associated valvular insufficiencies.
Neurological manifestations are not uncommon: recurrent headaches, transient focal neurological deficits, ischemic or hemorrhagic strokes. These may be related both to paradoxical thromboembolic events and
The diagnosis of Eisenmenger syndrome requires an integrated clinical and instrumental approach based on symptom analysis, physical examination, and advanced imaging and laboratory studies. Clinical suspicion arises in the presence of chronic central cyanosis, signs of pulmonary hypertension, and history of congenital heart disease with shunt, especially in patients without early surgical correction.
The diagnostic workup must follow a logical and progressive sequence tailored to the patient's age, clinical presentation, and anatomical complexity of the defect. Initially, a thorough medical history reconstructs cardiac history (known congenital defect, spontaneous or surgical closure, progressive symptoms such as dyspnea, cyanosis, syncope, hemoptysis). Physical examination may reveal cyanosis, digital clubbing, heart murmurs, jugular venous distension, signs of systemic congestion, or pulmonary findings suggestive of hypertension.
The first instrumental step is transthoracic echocardiography (TTE), which is the cornerstone for anatomical and functional assessment of the congenital heart disease and for diagnosing Eisenmenger syndrome. Echocardiography allows:
Color Doppler imaging provides detailed intracardiac flow analysis, enabling recognition of shunt reversal (from left-to-right to right-to-left) and quantification of the amount of deoxygenated blood entering the systemic circulation.
In cases of inconclusive findings, complex anatomy, or preoperative characterization needs, advanced imaging techniques such as cardiac magnetic resonance imaging (CMR) and cardiac computed tomography (CT) are employed. These modalities allow:
Right heart catheterization is the gold standard for hemodynamic diagnosis and severity assessment of Eisenmenger syndrome. It is indicated when:
Laboratory tests complete the work-up: blood count typically shows polycythemia and sometimes thrombocytopenia; liver and renal function tests identify organ complications; coagulation studies reveal thrombotic and hemorrhagic alterations. Arterial blood gas analysis documents hypoxemia and systemic desaturation.
The differential diagnosis must consider all forms of pulmonary hypertension (primary and secondary), congenital heart diseases without shunt reversal, and central cyanosis of other origins (hematologic, pulmonary diseases, methemoglobinemia). Distinguishing Eisenmenger syndrome from idiopathic pulmonary hypertension or “pure” congenital heart diseases without flow reversal is crucial to establish correct prognosis and treatment strategies.
Prognostic stratification is based on several parameters: NYHA functional class, degree of systemic desaturation, right ventricular function, presence of thromboembolic or hemorrhagic complications, and exercise tolerance. Periodic monitoring with echocardiography, exercise testing, laboratory evaluation, and advanced imaging is essential to track disease progression and guide therapeutic decisions.
Management of Eisenmenger syndrome is highly complex and requires a specialized multidisciplinary approach, often within adult congenital heart disease referral centers. The therapeutic goal is no longer anatomical correction of the defect, contraindicated due to irreversible pulmonary vascular damage, but rather improvement of quality of life, prevention and treatment of complications, and in selected cases access to advanced therapies or transplantation.
The pharmacological treatment includes various drug classes aimed at reducing pulmonary vascular resistance, controlling symptoms, and preventing thrombotic events:
A central aspect of management is complication prevention:
Invasive procedures and surgery are indicated only in exceptional cases and must be evaluated in ultra-specialized centers due to high perioperative mortality and risk of irreversible hypoxia worsening. Closure of the congenital defect is strictly contraindicated in established Eisenmenger syndrome, but may be considered only in patients with documented reversible pulmonary pressure during catheterization and acute vasodilator response.
For patients with symptoms refractory to medical therapy or progression to advanced heart failure, cardiopulmonary transplantation or sequential double transplantation (lungs + heart) represent the only definitive curative options. Transplantation is reserved for selected cases due to technical complexity, long-term immunosuppression requirements, and limited organ availability, but in eligible candidates can significantly prolong survival and improve quality of life.
The prognosis of Eisenmenger syndrome is variable and depends on multiple factors: type and size of the original defect, age at diagnosis, degree of hypoxemia and polycythemia, right ventricular function, presence of thromboembolic, hemorrhagic, or infectious complications, and response to specific therapy. Despite recent therapeutic advances, the syndrome remains associated with high morbidity and mortality, with average survival exceeding 30–40 years from diagnosis in well-compensated patients but significantly reduced in those with advanced heart failure or systemic complications.
A regular, structured multidisciplinary follow-up at expert centers is essential to monitor disease progression, prevent complications, adjust therapy, and provide psychosocial support to patients and families, aiming to improve prognosis and maintain the best possible quality of life.
Eisenmenger syndrome is characterized by extraordinary evolutionary complexity and a high risk of complications, which may arise at any disease stage and involve virtually every organ or system. Chronic hypoxemia, polycythemia, pulmonary hypertension, and right ventricular dysfunction act synergistically to produce a progressively deteriorating clinical picture, often unpredictable and potentially fatal.
The most relevant complications include:
The high incidence, severity, and overlap of these complications require continuous clinical surveillance, proactive emergency management, and comprehensive patient care focused both on prevention and timely identification and treatment of acute events.